Beyond One Indication: Unlocking the Full Potential of Orphan Drugs
Summary: Orphan drugs are essential for addressing unmet medical needs in rare diseases, but their development faces significant challenges, including small patient populations, high development costs, limited disease understanding, and complex regulatory pathways. Despite these hurdles, orphan drugs hold untapped potential to address multiple conditions beyond their initial indication. Expanding indications can help overcome market constraints, increase therapeutic impact, and foster sustainable innovation. This webinar will explore strategies for expanding indications for orphan drugs to maximize their therapeutic impact, unlock opportunities for innovation and collaboration, and address unmet needs across multiple conditions. Industry leaders will discuss how indication expansion can optimize R&D investments, balance ROI with patient access, and enable sustainable growth. Attendees will gain a comprehensive understanding of how pharmaceutical and biotech companies can leverage partnerships with Contract Development and Manufacturing Organizations (CDMOs). Experts will highlight how CDMOs can accelerate orphan drug development, provide scientific expertise to support and scale production to meet growing demands.
Speakers: Cornell Stamoran, Vice President, Strategy and Government Affairs, Catalent | Matthew Mollan Vice President, Operations, Early Phase Development, Catalent